NL-OMON22273招募中不适用
Observational Study;<br>Midazolam as CYP3A phenotyping probe to investigate the effects of lapatinib on hepatic CYP3A activity.
Erasmus MC-Daniel den HoedDepartment of Medical OncologyGroene Hilledijk 3013075 EA Rotterdamthe Netherlands0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Any patient who is going to be treated with lapatinib (1,250–1,500 mg once daily);
- •2. Age >= 18 years;
排除标准
- •1. Symptomatic CNS-metastases or a history of a psychiatric disorder that would prohibit the understanding and giving of informed consent;
- •2. Use of and/or unwillingness to abstain from grapefruit, grapefruit juice, star fruit, dietary supplements, herbal tea, herbals, and over-the-counter medication (except for acetaminophen (paracetamol) and ibuprofen) during the study period, starting 3 weeks before the first midazolam hydroxylation test and ending after the third test;
研究者
相似试验
招募中
不适用
Midazolam as a potential CYP3A phenotyping probe for cabazitaxel metabolism.prostate cancer - bone metastases10027476NL-OMON37899Meander Medisch Centrum15
已完成
不适用
Pharmacokinetics of the CYP3A substrate Midazolam after steady-state dosing of IMU-935.Chronic inflammatory diseasesautoimmune and chronic inflammatory diseasescastration-resistant prostate cancer1000381610036958NL-OMON51575Immunic AG16
已完成
1 期
A Study of LY2623091 in Healthy ParticipantsHealthy VolunteersNCT02300259Eli Lilly and Company48
已完成
不适用
In vivo CYP3A activity in palliative care patientsIn vivo CYP3A activity in palliative care patientsDRKS00011753niversitätsklinikum Heidelberg, Klinik für Anäthesiologie41
终止
1 期
A Tasisulam and Midazolam Drug Interaction Study in Cancer PatientsAdvanced CancerNCT01209832Eli Lilly and Company11